Coping with the effects of myocardial infarction from the viewpoint of patients' spouses.

The spouse of a patient who has experienced a myocardial infarction (MI) reportedly has psychological and social needs and challenges during the patient's hospitalization but there is a lack of knowledge regarding spouses' coping experiences and resources. The aim of this study was to develop a substantive theory to help explain the coping experiences of the spouse during the patient's hospitalization following an acute MI. Twenty eight spouses of patients in two Finnish hospitals participated in an open-ended interview within 2 to 5 days of the MI and included 12 husbands and 16 wives. The core category "Seeking balance" included the spouses' emotional, cognitive, and social coping experiences following an acute MI. This study adds new information about spouses' coping experiences as well as tensions and problems in interaction between the patient and the spouse. Challenges were reported in talking about serious illness concerns between the spouse and patient and also with other family members.

Spouses' coping alongside myocardial infarction patients.

BACKGROUND: The purpose of the research was to develop a substantive theory to describe the coping of myocardial infarction (MI) patients' spouses. The theory describes spousal coping experiences at 4 and 12 months after the patient's MI. METHODS: The data were collected by means of theme interviews from 28 spouses in the years 2006 and 2007 and analysed using Strauss and Corbin's grounded theory method. RESULTS: The substantive theory describes four main categories of spousal coping. The categories are: serene and balanced coping; action-centred coping; illness-centred coping; and coping based on denial of illness. CONCLUSIONS: The theory can be useful when developing support and counselling interventions for the spouses of MI patients. The study provides new knowledge about the spouses' coping experiences and about the factors that influence their coping over a longer period of time. The theory also discusses causal, contextual, and concurrent factors, which affect the coping experience and whose identification is important when seeking to support the spouses. Another application of the theory can be found in nursing education.

Coping Experiences: A Pathway towards Different Coping Orientations Four and Twelve Months after Myocardial Infarction-A Grounded Theory Approach.

Background. Patients recovering from a myocardial infarction (MI) are faced with a number of serious challenges. Aim. To create a substantive theory on myocardial infarction patients' coping as a continuum. Methods. Grounded theory method was used. Data were collected by using individual interviews. The informants were 28 MI patients. Results. The core category "coping experiences-a pathway towards different coping orientations" includes 2 main categories: "positive and negative coping experiences" (4 months after MI) and "different coping orientations" (12 months after MI). Conclusion. Coping with a myocardial infarction is a long-term dynamic process of dealing with varied emotions and adjustment needs. Coping is threatened, if the patient denies the seriousness of the situation, suffers from depression and emotional exhaustion, or if there are serious problems in the interaction with family members. This study stresses the importance of recognizing the patient's depressive state of mind and the psychological aspects which affect family dynamics. A more family-centered approach involving a posthospital counseling intervention is recommended. Relevance to Clinical Practice. The results of this study can be used in nursing care practice when organizing support interventions for myocardial infarction patients.

Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland.

BACKGROUND: The incidence of inflammatory bowel disease (IBD) is high in Western countries, but during the last decade the figures have stabilized, or only slightly increased; at the same time, an increasing incidence rate has been observed in Eastern Europe and Asia. The purpose of this study was to estimate the incidence of IBD in Finland between 2000 and 2007. METHODS: New IBD cases between 2000-2007 were retrieved from the national database of special reimbursements for drugs costs. The register includes virtually all Finnish IBD patients since 1986. The incidence rates were calculated per 100,000 persons assuming a Poisson distribution. RESULTS: In total, 14,214 IBD patients were identified; 10,352 had ulcerative colitis (UC) and 3,862 had Crohn's disease (CD). During the whole study period the mean annual incidence of IBD per 100,000 was 34.0: in CD 9.2 and in UC 24.8. The incidence of UC was notably higher in males (27.8) than in females (21.9). In CD the incidence rates did not differ significantly between genders. The incidence of UC increased from 22.1 in 2000-2001 to 27.4 in 2006-2007. The incidence of CD increased only slightly. CONCLUSION: In Finland, the incidence of IBD is high, and UC is almost three times more common than CD. During the new millennium the incidence rate of UC has increased, while the incidence rate of CD has remained fairly stable. To the best of our knowledge, the incidence of UC in this nationwide register study is one of the highest reported to date.

Coping--seeking lost control.

BACKGROUND: Acute myocardial infarction threatens patients' psychological balance and causes varied coping needs. AIM: The aim was to describe factors that influence patients' coping with acute MI during hospitalization. METHODS: The data were obtained by theme interviews from 28 myocardial infarction patients and analyzed by the grounded theory method. RESULTS: The core category "Coping with myocardial infarction: Seeking lost control" was found to include two main categories: factors supporting coping and factors interfering with coping. The factors were related to patients, conditions and interaction. CONCLUSION: Nurses need to become aware of their patients' needs to maintain a sense of control over their situation. They also need to focus on empowering counselling and mental support, and assist in patient-family interaction. Updating education on the recognition of depression and on the factors that affect coping is indicated. RELEVANCE TO CLINICAL PRACTICE: The findings of this study can be used in health care education and in nursing practice when organizing counselling and support interventions for MI patients.

Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.

This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53 years were recruited for the study. They were 1-5 years postmenopausal and their lumbar spine bone mineral density (BMD) was at least 1 standard deviation below the mean of premenopausal women ( T-score < or =-1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800 mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of 2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening, and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were -3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to 4.9%, p<0.0001)], and in the trochanter area BMD -1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5% in the clodronate group and -0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% ( p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% ( p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% ( p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% ( p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate in the extension phase. Clodronate in daily doses of 400-800 mg caused a slight elevation of aminotransferase levels, usually within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective, placebo-controlled trials.